AGT and persistent truncus arteriosus: The HHP-EXO ameliorated Ang II-induced cardiomyocyte hypertrophy in vitro and significantly improved cardiac remodeling and functions in the TAC-induced myocardial hypertrophy compared to its non-targeted counterpart.